Online Weight Loss Doctor Tennessee: Why I See Every Patient Myself

I’m in Chattanooga, and most weeks a patient calls in from Memphis, Knoxville, or Nashville having already tried an app first. They searched “online weight loss doctor Tennessee,” clicked the first result, filled out a questionnaire, and got a prescription. What they didn’t get was a doctor. I built Summit Metabolic Health to be the thing that search phrase actually promises — and I’m angry that it usually isn’t.

Type that phrase into Google and you’ll land on Ro, Hims, or Henry Meds before you land on an actual physician’s practice. Look closely at how those platforms work: an intake questionnaire, an algorithm that routes you to a prescribing clinician you’ll likely never speak to again, and a vial that ships. A clinician’s name is attached at the bottom of the approval. That’s not the same as a clinician who knows your case.

I don’t say this to score a point. I say it because I’ve watched what happens on the other end of that model — in my ER, at 2am, when a self-managed GLP-1 patient shows up in real trouble because nobody was actually watching the dose. The industry sells “easy to get.” It rarely sells “well managed.” Those are not the same product, and for a medication this powerful, the gap matters.

Here’s the part that should bother you more than it does. Dose escalation for semaglutide and tirzepatide isn’t a formality — it’s the single biggest lever for both how well the medication works and how badly a patient tolerates it. Move too fast and you get the nausea, vomiting, and GI distress that make people quit in month one. Move too slow and you leave results on the table. That decision requires someone who actually knows your history, your side-effect pattern, your labs.

An algorithm doesn’t know any of that. It knows what you typed into a form. When a flowchart — not a physician who’s read your chart — decides your next dose, the only variable it’s optimizing for is throughput: get you to the next tier, keep the subscription active. I’ve watched what that produces. It’s not a hypothetical for me. It’s a patient in my ER.

Here’s a question almost no app-based program answers honestly: what happens when your side effects don’t match the script? A questionnaire can ask you to rate your nausea on a scale of one to ten. It can’t hear the difference between “manageable, keep going” and “I’m not eating and I’m scared.” I can. That’s not a soft skill I’m bragging about — it’s the specific judgment call that determines whether a patient stays on a medication long enough to get the result, or quits in week three convinced it doesn’t work for them.

The headline numbers everyone quotes — up to 20.9% weight loss at 72 weeks for tirzepatide in SURMOUNT-1, 14.9% at 68 weeks for semaglutide in STEP 1 — didn’t happen because patients were handed a bottle and left alone.¹ ² They happened inside trials with scheduled dose titration, monitored side effects, and a clinician deciding when a patient was ready for the next step up.

Read that carefully: the adverse-event data from those same trials — the GI symptoms, the discontinuation rates — exists specifically because dose escalation was supervised and documented. The trials didn’t prove these drugs are safe when self-titrated by an app. They proved these drugs are safe and effective when a clinician manages the climb. Every online platform quoting SURMOUNT-1 or STEP 1 numbers to sell you a subscription is quoting results earned under a model of care they don’t actually provide.

I’m Dr. Paul Miranda. I’m a board-certified physician, and at Summit I personally review every chart — not a questionnaire run through software, not a nurse queue, not a rotating panel of clinicians who’ve never seen your case before. If you’re in Chattanooga, Knoxville, Nashville, Memphis, or anywhere else in Tennessee, the same person reads your intake, picks your medication with you, adjusts your dose to your actual tolerance, and is still there when you plateau or have a question at week eight.

That’s the entire reason I read every chart myself. I’m an ER physician by training. I’ve spent years now focused specifically on obesity medicine, and I built this practice because the alternative — a company optimizing for subscription revenue instead of your result — is the exact pattern I watch fail people in my day job.

Here’s where we won’t sugarcoat it: price is part of why people choose an app over a doctor, and I understand that. But look at what you’re actually being quoted. Hims runs an introductory rate that jumps to roughly $448 a month once the promotional pricing expires — a number most patients don’t see clearly until they’re already a few months in. Ro runs a similar pattern.

Summit’s pricing is transparent, descending-dose — $175–225/month all-in, and the number you’re quoted at your starting dose is the structure you’re on, not a teaser rate. I priced it that way on purpose. A patient managing a GLP-1 titration shouldn’t also have to budget for a pricing surprise three months from now. You get a real physician relationship at a lower steady-state cost than the app that never actually talks to you.

I’d rather you hear this from me up front than feel like you got played at month four: a lower headline price with an algorithm behind it isn’t actually cheaper if it costs you a canceled trip to your PCP’s office, a missed dose adjustment, or a subscription you keep paying because switching feels like starting over. The honest comparison isn’t month-one price against month-one price. It’s what you’re actually paying for — a vial that ships, or a physician who’s still reading your chart in month six.

If you’ve been quietly self-managing a prescription from an app, or you’re about to start one, ask the question the intake form never will: who is actually looking at your chart when your dose needs to change? If the honest answer is “an algorithm” or “whoever’s on shift,” that’s worth a second look.

I read every chart myself before we start anything, and I’ll tell you plainly if this program isn’t the right fit for your case — that’s part of the job, not a sales pitch dressed up as one. Summit sees patients across Tennessee by telehealth, based here in Chattanooga.

Ready to start? Apply at summitmetabolichealth.com/apply

¹ Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022. ² Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.

This post is for educational purposes and does not replace individualized medical evaluation. Weight loss outcomes vary by patient; the trial data cited here are group averages, not guarantees. Consult with a licensed physician before starting or changing any treatment.